131I-Zn-Chlorophyll derivative photosensitizer for tumor imaging and photodynamic therapy

Basit Öğe Kaydı
dc.contributor.authorOcakoglu K.
dc.contributor.authorEr O.
dc.contributor.authorKiyak G.
dc.contributor.authorLambrecht F.Y.
dc.contributor.authorGunduz C.
dc.contributor.authorKayabasi C.
dc.date.accessioned2019-10-26T21:22:12Z
dc.date.available2019-10-26T21:22:12Z
dc.date.issued2015
dc.departmentEge Üniversitesien_US
dc.description.abstractIn recent years, the photodynamic therapy studies have gained considerable attention as an alternative method to surgery, chemotherapy and radiotherapy which is commonly used to fight cancer. In this study, biological potentials of a benzyloxy bearing zinc(II) pheophorbide-a (Zn-PH-A) were investigated via in vivo and in vitro experiments. Zn-PH-A was labeled with 131I with high efficiency (95.3 ± 2.7%) and its biodistribution studies were investigated on female Albino Wistar rats. The radiolabeled photosensitizer had been intravenously injected into the tail vein, and then the animals were sacrificed at 30, 60 and 120 min post injection. The percent of radioactivity per gram of organs (%ID/g) was determined. The radiolabeled Zn-PH-A showed high uptake in ovary. In addition, photodynamic therapy studies of the photosensitizer were conducted in EMT6, murine mammary carcinoma and HeLa, human cervix carcinoma cell lines. For the photodynamic therapy studies, the cells with Zn-PH-A were exposed to red light (650 nm) at the doses of 10-30 J/cm2. The results showed that Zn-PH-A has stronger PDT effect in EMT6 than HeLa cell. Our present work demonstrates 131I-labeled photosensitizer as a bifunctional agent (PDT and nuclear imaging) which could be improved in future by using EMT6 growing tumor in nude mice. © 2015 Elsevier B.V. All rights reserved © 2015 Elsevier B.V. All rights reserved. © 2015 Elsevier B.V. All rights reserved.en_US
dc.description.sponsorship112T565en_US
dc.description.sponsorshipThe authors gratefully acknowledge financial support by The Scientific and Technological Research Council of Turkey, TUBITAK (Grant no: 112T565). --en_US
dc.identifier.doi10.1016/j.ijpharm.2015.07.047en_US
dc.identifier.endpage101en_US
dc.identifier.issn0378-5173
dc.identifier.issue01.Feben_US
dc.identifier.pmid26226337en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage96en_US
dc.identifier.urihttps://doi.org/10.1016/j.ijpharm.2015.07.047
dc.identifier.urihttps://hdl.handle.net/11454/16948
dc.identifier.volume493en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.ispartofInternational Journal of Pharmaceuticsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subject131Ien_US
dc.subjectBiodistributionen_US
dc.subjectCanceren_US
dc.subjectChlorophyllen_US
dc.subjectPhotodynamic therapyen_US
dc.subjectRadiolabelingen_US
dc.title131I-Zn-Chlorophyll derivative photosensitizer for tumor imaging and photodynamic therapyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu